Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase III KEYNOTE-564 study.
Year: 2021
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Toni K. Choueiri, Piotr Tomczak, Se Hoon Park, Balaji Venugopal, Tom Ferguson, Yen-Hwa Chang, Jaroslav Hajek, Stefan N. Symeonides, Jae-Lyun Lee, Naveed Sarwar, Antoine Thiery-Vuillemin, Marine Gross-Goupil, Mauricio Mahave, Naomi B. Haas, Piotr Sawrycki, Eric (Pingye) Zhang, Jaqueline Willemann Rogerio, Kentaro Imai, David I. Quinn, Thomas Powles
Institutions: Dana-Farber Cancer Institute, University Hospital of Lord’s Transfiguration, Samsung Medical Center, University of Glasgow, Royal Perth Hospital, Taipei Veterans General Hospital, University Hospital Ostrava, Edinburgh Cancer Research, University of Edinburgh, Asan Medical Center, University of Ulsan, Imperial College Healthcare NHS Trust, Centre Hospitalier Universitaire de Besançon, Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, Fundación Arturo López Pérez, Abramson Cancer Center, University of Pennsylvania, Provincial Polyclinical Hospital in Toruń, Merck & Co., Inc., Rahway, NJ, USA (United States), USC Norris Comprehensive Cancer Center, National Health Service, Queen Mary University of London, The Royal Free Hospital, Cancer Research UK, Barts Cancer Institute
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3167153458